反应详情

Following the procedure as described in EXAMPLE 13 and making non-critical variations using 1′-(4-hydroxybenzyl)-2,3-dihydrospiro[furo[2,3-g][1,4]benzodioxine-8,3′-indol]-2′(1H)-one to replace 1′-(3-hydroxybenzyl)-5,6-dihydrospiro[benzo[1,2-b:5,4-b′]difuran-3,3′-indol]-2′(1′H)-one, and 2-(dimethylamino)ethyl chloride hydrochloride to replace 2-iodoacetamide, 1′-{4-[2-(dimethylamino)ethoxy]benzyl}-2,3-dihydrospiro[furo[2,3-g][1,4]benzodioxine-8,3′-indol]-2′(1H)-one was obtained (26%) as a colorless solid: mp 77-79° C.; 1H NMR (300 MHz, CDCl3) δ 7.30-7.11 (m, 4H), 7.05-6.97 (m, 1H), 6.92-6.86 (m, 2H), 6.82-6.78 (m, 1H), 6.51 (s, 1H), 6.21 (s, 1H), 4.88 (ABq, J=77.2, 15.3 Hz, 2H), 4.79 (ABq, J=83.8, 8.9 Hz, 2H), 4.23-4.05 (m, 6H), 2.84-2.75 (m, 2H), 2.40 (s, 6H); 13C NMR (300 MHz, CDCl3) δ 177.5, 158.3, 155.2, 144.6, 142.1, 138.3, 132.3, 128.7, 127.9, 123.8, 123.3, 121.1, 114.9, 111.5, 109.3, 99.4, 80.2, 65.8, 64.5, 63.9, 58.2, 58.0, 45.8, 43.6; MS (ES+) m/z 472.8 (M+1).